MX2008015498A - Tratamiento de cancer de mama metastasico. - Google Patents

Tratamiento de cancer de mama metastasico.

Info

Publication number
MX2008015498A
MX2008015498A MX2008015498A MX2008015498A MX2008015498A MX 2008015498 A MX2008015498 A MX 2008015498A MX 2008015498 A MX2008015498 A MX 2008015498A MX 2008015498 A MX2008015498 A MX 2008015498A MX 2008015498 A MX2008015498 A MX 2008015498A
Authority
MX
Mexico
Prior art keywords
her2
treatment
breast cancer
metastatic breast
taxane
Prior art date
Application number
MX2008015498A
Other languages
English (en)
Inventor
Virginia Paton
Anne Blackwood Chirchir
Pam Klein
Grham Alexander Ross
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2008015498A publication Critical patent/MX2008015498A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se relaciona al tratamiento de cáncer de mama metastásico positivo a HER2 no tratado previamente con una combinación de un anticuerpo de HER2 inhibidor del crecimiento, un anticuerpo inhibidor de dimerización de HER2 y un taxeno. En particular, la invención se relaciona al tratamiento de cáncer de mama metastásico positivo a HER2 en pacientes que no reciben antes quimioterapia o terapia biológica con un anticuerpo de HER2 el cual enlaza esencialmente al epítopo 4D5, y un taxeno. La invención además comprende prolongar la sobrevivencia de tales pacientes por la terapia de combinación de la presente invención. En una modalidad preferida, el tratamiento implica la administración de trastuzumab, pertuzumab y docetaxel.
MX2008015498A 2008-06-16 2008-12-03 Tratamiento de cancer de mama metastasico. MX2008015498A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6196208P 2008-06-16 2008-06-16

Publications (1)

Publication Number Publication Date
MX2008015498A true MX2008015498A (es) 2010-02-17

Family

ID=40436247

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008015498A MX2008015498A (es) 2008-06-16 2008-12-03 Tratamiento de cancer de mama metastasico.

Country Status (7)

Country Link
US (6) US20090317387A1 (es)
AU (1) AU2008331354B2 (es)
BR (1) BRPI0812682A2 (es)
CA (1) CA2671223A1 (es)
MX (1) MX2008015498A (es)
MY (1) MY152864A (es)
WO (1) WO2009154651A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116271013A (zh) * 2011-10-14 2023-06-23 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
KR20160096228A (ko) 2004-07-22 2016-08-12 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006216732C1 (en) * 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8374703B2 (en) 2009-01-26 2013-02-12 Incube Labs, Llc Method and apparatus for the detection of aberrant neural-electric activity
US8609095B2 (en) * 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
US9393198B2 (en) * 2010-03-22 2016-07-19 Signpath Pharma Inc. Intravenous curcumin and derivatives for treatment of neurodegenerative and stress disorders
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
AU2011257121A1 (en) 2010-05-27 2013-01-10 Genmab A/S Monoclonal antibodies against HER2
CN103796677B (zh) * 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
CN103796678B (zh) * 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
US10532045B2 (en) 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10117881B2 (en) 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
US10449193B2 (en) 2011-06-03 2019-10-22 Signpath Pharma Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
US10238602B2 (en) 2011-06-03 2019-03-26 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10349884B2 (en) 2011-06-03 2019-07-16 Sighpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US8753674B2 (en) 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10220144B2 (en) * 2011-11-21 2019-03-05 Incube Labs, Llc Apparatus, systems and methods for the treatment of neurological conditions
JP2015502543A (ja) 2011-12-05 2015-01-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 乳癌治療向けベバシズマブ併用療法用血漿バイオマーカー
ES2431914B2 (es) * 2012-04-27 2014-07-24 Universidad De Cádiz Anticuerpo monoclonal humano ANTI-HER2
US9170257B2 (en) * 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
BR112014032456A2 (pt) 2012-06-26 2017-06-27 Hoffmann La Roche métodos in vitro, composição farmacêutica, kit para realização do método e método para melhorar o efeito de tratamento
WO2014036534A1 (en) 2012-08-31 2014-03-06 University Of North Texas Health Science Center Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
TWI482782B (zh) 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
MX2016006572A (es) 2013-11-27 2016-12-09 Zymeworks Inc Construcciones de union a antigenos biespecificas dirigidas a her2.
EP3134440A1 (en) 2014-04-25 2017-03-01 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2015195925A1 (en) 2014-06-18 2015-12-23 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates and methods of using same
EP3294772A4 (en) 2015-05-13 2019-05-01 Zymeworks Inc. BINDING CONSTRUCTS TO HER2 TARGETING ANTIGEN
EP3302551A2 (en) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
GB201520568D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3448374A4 (en) 2016-04-27 2020-01-08 Signpath Pharma Inc. PREVENTION OF DRUG-INDUCED ATRIO-VENTRICULAR BLOCK
JP2019532999A (ja) * 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳がんの治療
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
RU2750821C2 (ru) 2017-01-17 2021-07-05 Дженентек, Инк. Препараты антител против her2 для подкожного введения
FI3589661T3 (fi) 2017-03-02 2024-01-31 Genentech Inc Her2-positiivisen rintasyövän adjuvanttihoito
CN110536969A (zh) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 跨膜或近膜域中的erbb2/her2突变
US20200170972A1 (en) * 2018-11-30 2020-06-04 Strongbridge Dublin Limited Methods of treating disease with dichlorphenamide
RU2702294C1 (ru) * 2019-01-18 2019-10-07 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук ("Томский НИМЦ") Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu
RU2700109C1 (ru) * 2019-01-18 2019-09-12 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ радионуклидной диагностики вторичной отечно-инфильтративной формы рака молочной железы с гиперэкспрессией Her2/neu с использованием рекомбинантных адресных молекул DARPin9_29
US20220204644A1 (en) * 2019-05-02 2022-06-30 Mab Discovery Gmbh Combination of her2 antibodies
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JPH03505964A (ja) 1988-04-18 1991-12-26 アプライド・バイオテクノロジー・インコーポレーテッド ｎｅｕ遺伝子の発現及び遺伝子産物の検出
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US6884418B1 (en) 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
EP0444181B2 (en) 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft C-erbb-2 external domain: gp75
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
EP0656367A1 (en) 1991-08-22 1995-06-07 Becton, Dickinson and Company Method and composition for cancer therapy and for prognosticating responses to cancer theraphy
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU3236793A (en) 1991-12-12 1993-07-19 Berlex Laboratories, Inc. Recombinant and chimeric antibodies to c-erbB-2
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
WO1994009022A1 (en) 1992-10-09 1994-04-28 Oncor, Inc. Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue
ATE186219T1 (de) 1993-03-24 1999-11-15 Berlex Biosciences Kombination von antihormonale und bindende moleküle zur krebsbehandlung
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5846749A (en) 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
EP0711565B1 (en) 1994-11-10 1998-08-26 Eberhard-Karls-Universität Tübingen Universitätsklinikum Inhibiting growth of leukemic cells by targeting HER-2 protein
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5783404A (en) 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US5925519A (en) 1996-06-03 1999-07-20 The Regents Of The University Of California Genetic alterations associated with prostate cancer
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
NZ519191A (en) 1996-10-18 2005-04-29 Univ Texas Antibodies that bind to domain 1 of ErbB2 useful for inducing cell death via apoptosis, and nucleic acids encoding such antibodies
US6468547B1 (en) 1996-10-30 2002-10-22 Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
EP1864999B1 (en) 1996-11-27 2009-03-18 Genentech, Inc. Affinity purification of polypeptide on protein a matrix
CA2279547A1 (en) 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US20020076695A1 (en) 1997-04-04 2002-06-20 Jeffrey S. Ross Methods for treating prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6358682B1 (en) 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US20020192211A1 (en) 1998-03-17 2002-12-19 Hudziak Robert M. Method of treating tumor cells by inhibiting growth factor receptor function
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
ATE321066T1 (de) * 1998-05-06 2006-04-15 Genentech Inc Anti-her2 antikörperzusammensetzung
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
DE60041808D1 (de) 1999-01-27 2009-04-30 Cornell Res Foundation Inc Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6333348B1 (en) 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
ES2320311T3 (es) 1999-05-14 2009-05-21 Genentech, Inc. Tratamiento con anticuerpos anti-erbb2.
JP3485252B2 (ja) 1999-06-16 2004-01-13 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1189641B1 (en) 1999-06-25 2009-07-29 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
DK2283866T3 (en) 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
MXPA02000962A (es) 1999-07-29 2002-07-02 Medarex Inc Anticuerpos monoclonales humanos para her2/neu.
ES2330301T3 (es) 1999-08-27 2009-12-09 Genentech, Inc. Dosificaciones para tratamiento con anticuerpos anti-erbb2.
WO2001021192A2 (en) 1999-09-22 2001-03-29 Corixa Corporation Methods for diagnosis and therapy of hematological and virus-associated malignancies
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
AU2001227966A1 (en) 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors
US20030022918A1 (en) 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
US20200048362A1 (en) 2000-03-16 2020-02-13 Immunogen, Inc. Methods of treatment using anti-erbb antibody-maytansinoid conjugates
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6767541B2 (en) 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
WO2001076630A1 (fr) 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics et remedes contre la polyarthrite rhumatoide
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
CZ20023748A3 (cs) 2000-05-15 2003-04-16 Pharmacia Italia S.P.A. Inhibitory aromatasy a monoklonální anti-HER2 protilátky jako protitumorová činidla
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
TWI317285B (en) 2000-07-28 2009-11-21 Dainippon Sumitomo Pharma Co New use and kit for remedies for cancer
JP2004527456A (ja) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US20020142328A1 (en) 2000-12-01 2002-10-03 Danenberg Kathleen D. Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
CA2436910C (en) 2000-12-01 2014-06-17 Response Genetics, Inc. Method of determining epidermal growth factor receptor and her2-neu gene expression and correlation of levels thereof with survival rates
US7005278B2 (en) 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
WO2002045653A2 (en) 2000-12-08 2002-06-13 Uab Research Foundation Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
EP1349574A2 (en) 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2002087619A1 (fr) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
CA2449166A1 (en) 2001-05-08 2002-11-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-egfr antibodies and anti-hormonal agents
ITRM20010408A1 (it) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2.
WO2003012072A2 (en) 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
US20030068318A1 (en) 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer
EP1300146A1 (en) 2001-10-03 2003-04-09 Boehringer Ingelheim International GmbH Pharmaceutical composition for the treatment of animal mammary tumors
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030096823A1 (en) 2001-11-16 2003-05-22 Beryl Asp Method for the treatment of cardiotoxicity induced by antitumor compounds
US20040048525A1 (en) 2002-01-28 2004-03-11 Sagucio Esteban N. Watercycle for wet rider
US20030175845A1 (en) 2002-03-13 2003-09-18 Kalbag Suresh M. Use of sulfitolysis in high performance peptide mapping
EP2258872B1 (en) 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20030190689A1 (en) 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
JP2005534623A (ja) 2002-04-08 2005-11-17 スミスクライン ビーチャム コーポレーション Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
CA2481515C (en) 2002-04-10 2013-10-01 Genentech, Inc. Anti-her2 antibody variants
ITTO20020340A1 (it) 2002-04-19 2003-10-20 Biother Di Contardi Gabriella Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato.
US20030202973A1 (en) 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
CZ297625B6 (cs) 2002-07-03 2007-02-14 Zpusob cistení pylu a zarízení k provádení tohotozpusobu
PT1585966E (pt) 2002-07-15 2012-02-20 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 rhumab 2c4
US20040013297A1 (en) 2002-07-18 2004-01-22 Roger Lo Method for performing color gamut compression
ES2629602T5 (es) 2002-09-11 2021-06-08 Genentech Inc Purificación de proteínas
WO2004048525A2 (en) 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
AU2003302821B2 (en) 2002-12-11 2009-05-07 Cell Signaling Technology, Inc. Method for predicting the response to HER2-directed therapy
WO2004063709A2 (en) 2003-01-08 2004-07-29 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20050025753A1 (en) 2003-04-30 2005-02-03 Wei Han Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
ES2786568T3 (es) 2003-07-28 2020-10-13 Genentech Inc Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20160096228A (ko) 2004-07-22 2016-08-12 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ZA200704796B (en) 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
KR20090019890A (ko) 2006-06-05 2009-02-25 제넨테크, 인크. Ｅｇｆ 또는 ｔｇｆ-알파 수준이 상승된 암 환자의 생존 연장
EP2441472B1 (en) 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
WO2008148546A2 (en) 2007-06-06 2008-12-11 F.Hoffmann-La Roche Ag Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
RS53850B2 (sr) 2007-10-30 2018-07-31 Genentech Inc Pročišćavanje antitela hromatografijom izmene katjona
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
TW200942552A (en) * 2008-03-06 2009-10-16 Genentech Inc Combination therapy with c-Met and HER antagonists
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
US9235334B2 (en) 2008-05-09 2016-01-12 Genesis Industries, Llc Managing landbases and machine operations performed thereon
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2648719A1 (en) 2010-12-09 2013-10-16 F.Hoffmann-La Roche Ag Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
DK2766040T3 (da) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
AR095863A1 (es) 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
EP3083692B1 (en) 2013-12-17 2020-02-19 F.Hoffmann-La Roche Ag Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
EP3134440A1 (en) 2014-04-25 2017-03-01 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP2019532999A (ja) 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳がんの治療
CN110099926A (zh) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
RU2750821C2 (ru) 2017-01-17 2021-07-05 Дженентек, Инк. Препараты антител против her2 для подкожного введения
FI3589661T3 (fi) 2017-03-02 2024-01-31 Genentech Inc Her2-positiivisen rintasyövän adjuvanttihoito
CN114344486A (zh) 2017-10-20 2022-04-15 生物技术公司 适用于治疗的脂质体rna制剂的制备和储存
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
CA3188134A1 (en) 2020-07-14 2022-01-20 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
TW202237136A (zh) 2020-12-11 2022-10-01 美商建南德克公司 用於治療ｈｅｒ２癌症的組合療法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116271013A (zh) * 2011-10-14 2023-06-23 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品

Also Published As

Publication number Publication date
AU2008331354A1 (en) 2010-01-07
US20230250187A1 (en) 2023-08-10
US20090317387A1 (en) 2009-12-24
US20170029527A1 (en) 2017-02-02
US10689457B2 (en) 2020-06-23
CA2671223A1 (en) 2009-12-16
US20140044704A1 (en) 2014-02-13
US20150037332A1 (en) 2015-02-05
BRPI0812682A2 (pt) 2010-06-22
US20210047429A1 (en) 2021-02-18
WO2009154651A1 (en) 2009-12-23
AU2008331354B2 (en) 2014-11-20
MY152864A (en) 2014-11-28
US11655305B2 (en) 2023-05-23

Similar Documents

Publication Publication Date Title
MY152864A (en) Treatment of metastatic breast cancer
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
HK1243943A1 (zh) 使用抗IL-1α抗體治療癌症
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MX2018010331A (es) Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos.
AR062840A1 (es) Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2)
WO2016059602A3 (en) Combination therapy with anti-her3 antibodies to treat cancer
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
MX358728B (es) Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
MX2021014137A (es) Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo.
UA94899C2 (ru) Фиксированное дозирование антител к her
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2010003520A3 (en) Anti-tumor immunotherapy
WO2011146568A8 (en) Predicting response to a her inhibitor
MX340724B (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama.
NZ601588A (en) Methods for treating breast cancer
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
NZ625758A (en) Method for treating breast cancer
MX2012001745A (es) Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted